{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:40:24Z","timestamp":1793497224994,"version":"4.5.0"},"reference-count":397,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50 million people were living with chronic hepatitis C based on the World Health Organization as of 2024, contributing extensively to global morbidity and mortality. The advent and approval of several direct-acting antiviral (DAA) regimens significantly improved HCV treatment, offering potentially high rates of cure for chronic hepatitis C. However, the promising aim of eventual HCV eradication remains challenging. Key challenges include the variability in DAA access across different regions, slightly variable response rates to DAAs across diverse patient populations and HCV genotypes\/subtypes, and the emergence of resistance-associated substitutions (RASs), potentially conferring resistance to DAAs. Therefore, periodic reassessment of current HCV knowledge is needed. An up-to-date review on HCV is also necessitated based on the observed shifts in HCV epidemiological trends, continuous development and approval of therapeutic strategies, and changes in public health policies. Thus, the current comprehensive review aimed to integrate the latest knowledge on the epidemiology, pathophysiology, diagnostic approaches, treatment options and preventive strategies for HCV, with a particular focus on the current challenges associated with RASs and ongoing efforts in vaccine development. This review sought to provide healthcare professionals, researchers, and policymakers with the necessary insights to address the HCV burden more effectively. We aimed to highlight the progress made in managing and preventing HCV infection and to highlight the persistent barriers challenging the prevention of HCV infection. The overarching goal was to align with global health objectives towards reducing the burden of chronic hepatitis, aiming for its eventual elimination as a public health threat by 2030.<\/jats:p>","DOI":"10.3390\/microorganisms12061035","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T06:50:52Z","timestamp":1716274252000},"page":"1035","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Contemporary Insights into Hepatitis C Virus: A Comprehensive Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0165-9670","authenticated-orcid":false,"given":"Malik","family":"Sallam","sequence":"first","affiliation":[{"name":"Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan"},{"name":"Department of Clinical Laboratories and Forensic Medicine, Jordan University Hospital, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roaa","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3961\/jpmph.21.151","article-title":"Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination","volume":"54","author":"Brunner","year":"2021","journal-title":"J. Prev. Med. Public Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1041201","DOI":"10.3389\/fpubh.2023.1041201","article-title":"The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019","volume":"11","author":"Yang","year":"2023","journal-title":"Front. Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/livers4020013","article-title":"The Epidemiology of Chronic Hepatitis C: Where We Are Now","volume":"4","author":"Stasi","year":"2024","journal-title":"Livers"},{"key":"ref_4","unstructured":"World Health Organization (WHO) (2024, April 19). Hepatitis C\u2014Key Facts. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement","volume":"323","author":"Owens","year":"2020","journal-title":"JAMA"},{"key":"ref_6","unstructured":"World Health Organization (WHO) (2024, May 15). Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection, and HCV Simplified Service Delivery and Diagnostics. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240052734."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","article-title":"New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives","volume":"61","author":"Welsch","year":"2012","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1093\/cid\/ciad344","article-title":"Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review","volume":"77","author":"Martinello","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review","volume":"166","author":"Nelson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","article-title":"New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials","volume":"9","author":"Pecoraro","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_13","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., and Lo Re, V. (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., ciad319."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"AASLD-IDSA HCV Guidance Panel (2018). Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., 67, 1477\u20131492.","DOI":"10.1093\/cid\/ciy585"},{"key":"ref_15","first-page":"113","article-title":"Hepatitis C virus proteins: From structure to function","volume":"369","author":"Moradpour","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: From discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100462","DOI":"10.1016\/j.jhepr.2022.100462","article-title":"Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals","volume":"4","author":"Howe","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_18","first-page":"Cd012143","article-title":"Direct-acting antivirals for chronic hepatitis C","volume":"9","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Int. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Howe, A.Y.M., Ceccherini-Silberstein, F., Dietz, J., Popping, S., Grebely, J., Rodrigo, C., Lennerstrand, J., Douglas, M.W., Parczewsk, M., and Harrigan, P.R. (2021). SHARED: An International Collaboration to Unravel Hepatitis C Resistance. Viruses, 13.","DOI":"10.3390\/v13081580"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","article-title":"Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies","volume":"248","author":"Bartenschlager","year":"2018","journal-title":"Virus Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4254\/wjh.v9.i33.1239","article-title":"Global elimination of hepatitis C virus infection: Progresses and the remaining challenges","volume":"9","author":"Taherkhani","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hartlage, A.S., and Kapoor, A. (2021). Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up. Viruses, 13.","DOI":"10.3390\/v13081596"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4254\/wjh.v7.i6.831","article-title":"Hepatitis C virus genetic variability and evolution","volume":"7","author":"Moratorio","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_25","first-page":"274","article-title":"Protective immunity against hepatitis C: Many shades of gray","volume":"5","author":"Shoukry","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/liv.14011","article-title":"Hepatitis C: Is eradication possible?","volume":"39","author":"Lombardi","year":"2019","journal-title":"Liver Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable","volume":"16","author":"Dhiman","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"a036939","DOI":"10.1101\/cshperspect.a036939","article-title":"The Elimination of Hepatitis C as a Public Health Threat","volume":"10","author":"Hellard","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tim.2013.09.008","article-title":"Treatment as prevention and cure towards global eradication of hepatitis C virus","volume":"21","author":"Hagan","year":"2013","journal-title":"Trends Microbiol."},{"key":"ref_31","first-page":"e43924","article-title":"Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions","volume":"15","author":"Bernal","year":"2023","journal-title":"Cureus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4254\/wjh.v13.i9.1069","article-title":"Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions","volume":"13","author":"Ridruejo","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/17425255.2016.1209484","article-title":"Hepatitis C virus resistance to the new direct-acting antivirals","volume":"12","author":"Esposito","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"894460","DOI":"10.3389\/fphar.2022.894460","article-title":"Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals","volume":"13","author":"Mushtaq","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kyuregyan, K.K., Kichatova, V.S., Karlsen, A.A., Isaeva, O.V., Solonin, S.A., Petkov, S., Nielsen, M., Isaguliants, M.G., and Mikhailov, M.I. (2020). Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicines, 8.","DOI":"10.3390\/biomedicines8040080"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"a037069","DOI":"10.1101\/cshperspect.a037069","article-title":"Hepatitis C Virus: 30 Years after Its Discovery","volume":"9","author":"Houghton","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM197504102921502","article-title":"Transfusion-associated hepatitis not due to viral hepatitis type A or B","volume":"292","author":"Feinstone","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(90)90134-Q","article-title":"Detection of hepatitis C viral sequences in non-A, non-B hepatitis","volume":"335","author":"Weiner","year":"1990","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(78)90131-9","article-title":"Transmissible agent in non-A, non-B hepatitis","volume":"1","author":"Alter","year":"1978","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000148969","article-title":"Non-A, non-B hepatitis transmission in chimpanzees: A project of the transfusion-transmitted viruses study group","volume":"10","author":"Hollinger","year":"1978","journal-title":"Intervirology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.451589","article-title":"Non-A, non-B hepatitis: Ultrastructural evidence for two agents in experimentally infected chimpanzees","volume":"205","author":"Shimizu","year":"1979","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0166-0934(85)90047-3","article-title":"The agents of non-A, non-B viral hepatitis","volume":"10","author":"Bradley","year":"1985","journal-title":"J. Virol. Methods"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0016-5085(85)90150-7","article-title":"Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus","volume":"88","author":"Bradley","year":"1985","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jceh.2020.04.006","article-title":"The Discovery of Hepatitis Viruses: Agents and Disease","volume":"10","author":"Khuroo","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41435-019-0066-z","article-title":"The remarkable history of the hepatitis C virus","volume":"20","author":"Pol","year":"2019","journal-title":"Genes. Immun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000050040","article-title":"Studies of hepatitis C virus in chimpanzees and their importance for vaccine development","volume":"44","author":"Bukh","year":"2001","journal-title":"Intervirology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000060482","article-title":"Biological and immunological aspects of hepatitis C virus infection in chimpanzees","volume":"62","author":"Prince","year":"1998","journal-title":"Curr. Stud. Hematol. Blood Transfus."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1073\/pnas.87.3.983","article-title":"Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: Application to diagnosis and blood screening for posttransfusion hepatitis","volume":"87","author":"Miyamura","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/hep.31830","article-title":"The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1073\/pnas.87.6.2057","article-title":"Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups","volume":"87","author":"Miller","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0014-5793(91)80322-T","article-title":"Molecular structure of the Japanese hepatitis C viral genome","volume":"280","author":"Kato","year":"1991","journal-title":"FEBS Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.277.5325.570","article-title":"Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA","volume":"277","author":"Kolykhalov","year":"1997","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Taha, G., Ezra, L., and Abu-Freha, N. (2023). Hepatitis C Elimination: Opportunities and Challenges in 2023. Viruses, 15.","DOI":"10.3390\/v15071413"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1007\/s42399-020-00588-3","article-title":"Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination","volume":"2","author":"Stasi","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2007-1007262","article-title":"Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes","volume":"15","author":"Bukh","year":"1995","journal-title":"Semin. Liver Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1046\/j.1440-1746.17.s4.12.x","article-title":"Hepatitis C virus: Clades and properties","volume":"17","author":"Howard","year":"2002","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev-virology-100114-055104","article-title":"The Strange, Expanding World of Animal Hepaciviruses","volume":"3","author":"Hartlage","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_63","first-page":"1","article-title":"The origin of hepatitis C virus","volume":"369","author":"Simmonds","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1038\/emi.2014.19","article-title":"Natural reservoirs for homologs of hepatitis C virus","volume":"3","author":"Pfaender","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_66","unstructured":"Sallam, M. (2017). Phylogenetic Inference in the Epidemiologic and Evolutionary Investigation of HIV-1, HCV and HBV, Faculty of Medicine, Lund University."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: Molecular Evolutionary Genetics Analysis version 6.0","volume":"30","author":"Tamura","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gray, R.R., Parker, J., Lemey, P., Salemi, M., Katzourakis, A., and Pybus, O.G. (2011). The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol. Biol., 11.","DOI":"10.1186\/1471-2148-11-131"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2893.2008.00991.x","article-title":"Genetic variability in hepatitis C virus and its role in antiviral treatment response","volume":"15","author":"Cuevas","year":"2008","journal-title":"J. Viral Hepat."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: A systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"13","author":"Zein","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Martinez, M.A., and Franco, S. (2020). Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses, 13.","DOI":"10.3390\/v13010041"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2017.04.007","article-title":"Functional RNA structures throughout the Hepatitis C Virus genome","volume":"24","author":"Adams","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrmicro3506","article-title":"The yin and yang of hepatitis C: Synthesis and decay of hepatitis C virus RNA","volume":"13","author":"Li","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1743-422X-8-161","article-title":"An overview of HCV molecular biology, replication and immune responses","volume":"8","author":"Ashfaq","year":"2011","journal-title":"Virol. J."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Niepmann, M., and Gerresheim, G.K. (2020). Hepatitis C Virus Translation Regulation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072328"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/jvi.68.3.1494-1500.1994","article-title":"Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses","volume":"68","author":"Shimizu","year":"1994","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3389\/fimmu.2018.02146","article-title":"Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry","volume":"9","author":"Prentoe","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lapa, D., Garbuglia, A.R., Capobianchi, M.R., and Del Porto, P. (2019). Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?. Cells, 8.","DOI":"10.3390\/cells8040305"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3748\/wjg.v13.i17.2406","article-title":"Hepatitis C virus proteins","volume":"13","author":"Dubuisson","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Boukadida, C., Fritz, M., Blumen, B., Fogeron, M.L., Penin, F., and Martin, A. (2018). NS2 proteases from hepatitis C virus and related hepaciviruses share composite active sites and previously unrecognized intrinsic proteolytic activities. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006863"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Romero-Brey, I., Merz, A., Chiramel, A., Lee, J.Y., Chlanda, P., Haselman, U., Santarella-Mellwig, R., Habermann, A., Hoppe, S., and Kallis, S. (2012). Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1003056"},{"key":"ref_85","unstructured":"Tan, S.L. (2006). Hepatitis C Viruses: Genomes and Molecular Biology, Horizon Bioscience."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.3390\/v7072808","article-title":"Using the Hepatitis C Virus RNA-Dependent RNA Polymerase as a Model to Understand Viral Polymerase Structure, Function and Dynamics","volume":"7","author":"Sesmero","year":"2015","journal-title":"Viruses"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3350\/cmh.2022.0032","article-title":"Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment","volume":"29","author":"Park","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_88","unstructured":"Centers for Disease Control and Prevention (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep., 47, 1\u201339."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Sidorkiewicz, M. (2021). Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites, 11.","DOI":"10.3390\/metabo11050273"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.3748\/wjg.v27.i28.4555","article-title":"Cellular factors involved in the hepatitis C virus life cycle","volume":"27","author":"Li","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00535-012-0661-5","article-title":"Role of miR-122 and lipid metabolism in HCV infection","volume":"48","author":"Fukuhara","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/v6020535","article-title":"CD81 and hepatitis C virus (HCV) infection","volume":"6","author":"Levy","year":"2014","journal-title":"Viruses"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Mailly, L., and Baumert, T.F. (2020). Hepatitis C virus infection and tight junction proteins: The ties that bind. Biochim. Biophys. Acta Biomembr., 1862.","DOI":"10.1016\/j.bbamem.2020.183296"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Russelli, G., Pizzillo, P., Iannolo, G., Barbera, F., Tuzzolino, F., Liotta, R., Traina, M., Vizzini, G., Gridelli, B., and Badami, E. (2017). HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181683"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"775098","DOI":"10.3389\/fimmu.2021.775098","article-title":"A Role for B Cells to Transmit Hepatitis C Virus Infection","volume":"12","author":"Desombere","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_96","first-page":"3","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_97","first-page":"356","article-title":"Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus","volume":"85","author":"Crovatto","year":"2000","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chigbu, D.I., Loonawat, R., Sehgal, M., Patel, D., and Jain, P. (2019). Hepatitis C Virus Infection: Host-Virus Interaction and Mechanisms of Viral Persistence. Cells, 8.","DOI":"10.3390\/cells8040376"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kemming, J., Thimme, R., and Neumann-Haefelin, C. (2020). Adaptive Immune Response against Hepatitis C Virus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165644"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Patra, T., Ray, R.B., and Ray, R. (2019). Strategies to Circumvent Host Innate Immune Response by Hepatitis C Virus. Cells, 8.","DOI":"10.3390\/cells8030274"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2217\/fvl.14.89","article-title":"Hepatitis C Virus. Strategies to Evade Antiviral Responses","volume":"9","author":"Gokhale","year":"2014","journal-title":"Future Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1574-6976.2011.00319.x","article-title":"Failure of innate and adaptive immune responses in controlling hepatitis C virus infection","volume":"36","author":"Thimme","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"a036988","DOI":"10.1101\/cshperspect.a036988","article-title":"Innate Immunity in Hepatitis C Virus Infection","volume":"11","author":"Schwerk","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.apsb.2014.06.010","article-title":"Recent advances in the anti-HCV mechanisms of interferon","volume":"4","author":"Huang","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1743-422X-3-66","article-title":"Hepatitis C virus NS2 and NS3\/4A proteins are potent inhibitors of host cell cytokine\/chemokine gene expression","volume":"3","author":"Kaukinen","year":"2006","journal-title":"Virol. J."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Ferreira, A.R., Ramos, B., Nunes, A., and Ribeiro, D. (2020). Hepatitis C Virus: Evading the Intracellular Innate Immunity. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030790"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1128\/JVI.75.13.6095-6106.2001","article-title":"Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response","volume":"75","author":"Polyak","year":"2001","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"a037101","DOI":"10.1101\/cshperspect.a037101","article-title":"Control of HCV Infection by Natural Killer Cells and Macrophages","volume":"10","author":"Rosen","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20011124","article-title":"Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein","volume":"195","author":"Crotta","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12026-009-8152-3","article-title":"Hepatitis C virus evasion of adaptive immune responses: A model for viral persistence","volume":"47","author":"Burke","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Luxenburger, H., Neumann-Haefelin, C., Thimme, R., and Boettler, T. (2018). HCV-Specific T Cell Responses During and After Chronic HCV Infection. Viruses, 10.","DOI":"10.3390\/v10110645"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/JVI.76.12.6104-6113.2002","article-title":"Comprehensive analysis of CD8+-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities","volume":"76","author":"Lauer","year":"2002","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/1319-3767.133007","article-title":"Effect of HLA on hepatitis C virus clearance and persistence in anti-HCV-positive end-stage renal disease patients","volume":"20","author":"Ocal","year":"2014","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1053\/j.gastro.2010.09.042","article-title":"Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes","volume":"140","author":"Kim","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/gut.2010.228403","article-title":"Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection","volume":"60","author":"Fitzmaurice","year":"2011","journal-title":"Gut"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/hep.24541","article-title":"Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations","volume":"54","author":"Kuntzen","year":"2011","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1128\/JVI.76.10.4792-4797.2002","article-title":"HLA-Cw*04 and hepatitis C virus persistence","volume":"76","author":"Thio","year":"2002","journal-title":"J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/hep.23515","article-title":"Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia","volume":"51","author":"Kuniholm","year":"2010","journal-title":"Hepatology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/v1020104","article-title":"Role of host genetic factors in the outcome of hepatitis C virus infection","volume":"1","author":"Bengsch","year":"2009","journal-title":"Viruses"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fimmu.2015.00552","article-title":"HLA Preferences for Conserved Epitopes: A Potential Mechanism for Hepatitis C Clearance","volume":"6","author":"Rao","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0168-8278(99)80250-5","article-title":"HLA class II favors clearance of HCV infection and progression of the chronic liver damage","volume":"30","author":"Mangia","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.3748\/wjg.v11.i46.7302","article-title":"Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: A meta-analysis","volume":"11","author":"Hong","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1128\/JVI.76.24.12584-12595.2002","article-title":"Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection","volume":"76","author":"Day","year":"2002","journal-title":"J. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(08)61116-2","article-title":"Acute hepatitis C","volume":"372","author":"Maheshwari","year":"2008","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jhep.2016.04.030","article-title":"Factors associated with spontaneous clearance of chronic hepatitis C virus infection","volume":"65","author":"Bulteel","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.12.010","article-title":"Immune responses to HCV and other hepatitis viruses","volume":"40","author":"Park","year":"2014","journal-title":"Immunity"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5604\/16652681.1184193","article-title":"Hepatitis C virus strategies to evade the specific-T cell response: A possible mission favoring its persistence","volume":"15","author":"Quarleri","year":"2016","journal-title":"Ann. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3748\/wjg.v16.i16.1953","article-title":"Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity","volume":"16","author":"Wang","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2014.00550","article-title":"The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development","volume":"5","author":"Cashman","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1128\/JVI.00995-07","article-title":"Viral sequence evolution in acute hepatitis C virus infection","volume":"81","author":"Kuntzen","year":"2007","journal-title":"J. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1038\/s41467-022-33035-z","article-title":"Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C","volume":"13","author":"Nishio","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3389\/fimmu.2018.00910","article-title":"Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies","volume":"9","author":"Lavie","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Ortega-Prieto, A.M., and Dorner, M. (2017). Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines, 5.","DOI":"10.3390\/vaccines5030024"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"10596","DOI":"10.1038\/s41598-019-46664-0","article-title":"Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver","volume":"9","author":"Budzinska","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13337-020-00592-0","article-title":"HCV genotypes and their determinative role in hepatitis C treatment","volume":"31","author":"Keikha","year":"2020","journal-title":"Virusdisease"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"101596","DOI":"10.1016\/j.clinre.2020.101596","article-title":"Epidemiology of hepatitis C virus infection","volume":"45","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Zaltron, S., Spinetti, A., Biasi, L., Baiguera, C., and Castelli, F. (2012). Chronic HCV infection: Epidemiological and clinical relevance. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-S2-S2"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.idc.2017.07.014","article-title":"Hepatitis C Virus Infection in the Older Patient","volume":"31","author":"Reid","year":"2017","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","article-title":"The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt","volume":"355","author":"Frank","year":"2000","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","article-title":"HCV transmission in industrialized countries and resource-constrained areas","volume":"11","author":"Thursz","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: A modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0168-8278(99)80384-5","article-title":"Hepatitis C virus and blood transfusion: Past and present risks","volume":"31","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00430-017-0505-2","article-title":"Aspects on the history of transmission and favor of distribution of viruses by iatrogenic action: Perhaps an example of a paradigm of the worldwide spread of HIV","volume":"206","author":"Eberle","year":"2017","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Forni, D., Cagliani, R., Pontremoli, C., Pozzoli, U., Vertemara, J., De Gioia, L., Clerici, M., and Sironi, M. (2018). Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00854"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13337-016-0345-5","article-title":"Risky exposures and national estimate of HCV seroprevalence among school children in urban Egypt","volume":"27","author":"Shatat","year":"2016","journal-title":"Virusdisease"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1665-2681(19)31720-X","article-title":"Routes of transmission of hepatitis C virus","volume":"9","author":"Soza","year":"2010","journal-title":"Ann. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.5114\/aoms.2019.83644","article-title":"Perinatal transmission of hepatitis C virus: An update","volume":"16","author":"Kamal","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e25348","DOI":"10.1002\/jia2.25348","article-title":"Sexually transmitted hepatitis C virus infections: Current trends, and recent advances in understanding the spread in men who have sex with men","volume":"22","author":"Nijmeijer","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.23808","article-title":"Is sexual contact a major mode of hepatitis C virus transmission?","volume":"52","author":"Tohme","year":"2010","journal-title":"Hepatology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4254\/wjh.v8.i5.273","article-title":"Hepatitis B virus and hepatitis C virus infection in healthcare workers","volume":"8","author":"Coppola","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_152","first-page":"9270","article-title":"Epidemiology and natural history of hepatitis C virus infection","volume":"20","author":"Lee","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Hajarizadeh, B., Grady, B., Page, K., Kim, A.Y., McGovern, B.H., Cox, A.L., Rice, T.M., Sacks-Davis, R., Bruneau, J., and Morris, M. (2015). Patterns of hepatitis C virus RNA levels during acute infection: The InC3 study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122232"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1128\/JCM.36.4.872-877.1998","article-title":"Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels","volume":"36","author":"Beld","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"eaao4496","DOI":"10.1126\/scitranslmed.aao4496","article-title":"Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users","volume":"10","author":"Major","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1128\/JCM.43.9.4413-4417.2005","article-title":"Quantitative detection of hepatitis C virus (HCV) RNA in saliva and gingival crevicular fluid of HCV-infected patients","volume":"43","author":"Suzuki","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Pfaender, S., Helfritz, F.A., Siddharta, A., Todt, D., Behrendt, P., Heyden, J., Riebesehl, N., Willmann, W., Steinmann, J., and M\u00fcnch, J. (2018). Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00504"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1086\/420935","article-title":"Viral hepatitis transmission in ambulatory health care settings","volume":"38","author":"Williams","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_159","first-page":"22","article-title":"Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers","volume":"31","author":"Puro","year":"2003","journal-title":"Infection"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1086\/497131","article-title":"Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: A European case-control study","volume":"41","author":"Yazdanpanah","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.ajic.2017.03.011","article-title":"Seroconversion rates among health care workers exposed to hepatitis C virus-contaminated body fluids: The University of Pittsburgh 13-year experience","volume":"45","author":"Egro","year":"2017","journal-title":"Am. J. Infect. Control"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Alfulayw, K.H., Al-Otaibi, S.T., and Alqahtani, H.A. (2021). Factors associated with needlestick injuries among healthcare workers: Implications for prevention. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-07110-y"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(05)80094-7","article-title":"Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel","volume":"16","author":"Hernandez","year":"1992","journal-title":"J. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/jis677","article-title":"Transmission of hepatitis C virus among people who inject drugs: Viral stability and association with drug preparation equipment","volume":"207","author":"Doerrbecker","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/cid\/cir991","article-title":"Transmission of hepatitis C virus infection through tattooing and piercing: A critical review","volume":"54","author":"Tohme","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Sallam, M., Batarseh, R., Natsheh, A., Abbadi, J., Al-Fraihat, E., Yaseen, A., Kaddomi, D., Khamees, N., Mahafzah, A., and \u015eahin, G.\u00d6. (2019). An update on hepatitis C virus genotype distribution in Jordan: A 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-019-4735-3"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hep.26164","article-title":"Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study","volume":"57","author":"Terrault","year":"2013","journal-title":"Hepatology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1071\/SH16141","article-title":"Sexual transmission of hepatitis C virus among gay and bisexual men: A systematic review","volume":"14","author":"Jin","year":"2017","journal-title":"Sex. Health"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/jmv.21480","article-title":"Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages","volume":"81","author":"Shebl","year":"2009","journal-title":"J. Med. Virol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, I., Ryan, P., Valencia, J., and Resino, S. (2021). The Challenging Road to Hepatitis C Virus Eradication. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040611"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"De Siervi, S., Cannito, S., and Turato, C. (2023). Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310633"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_174","unstructured":"Polaris Observatory (2024, April 26). Hepatitis C Countries\/Territories\u2014Distribution. Available online: https:\/\/cdafound.org\/polaris-countries-distribution\/."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/HMER.S113681","article-title":"Hepatitis C infection in Egypt: Prevalence, impact and management strategies","volume":"9","author":"Gomaa","year":"2017","journal-title":"Hepat. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ije\/dyaa052","article-title":"Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt","volume":"49","author":"Ayoub","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Rao, M.R., Naficy, A.B., Darwish, M.A., Darwish, N.M., Schisterman, E., Clemens, J.D., and Edelman, R. (2002). Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect. Dis., 2.","DOI":"10.1186\/1471-2334-2-29"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_179","first-page":"p2353","article-title":"Hepatitis C: Egypt makes \u201cunprecedented progress\u201d towards elimination","volume":"383","author":"Elisabeth","year":"2023","journal-title":"BMJ"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1099\/0022-1317-74-11-2391","article-title":"Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region","volume":"74","author":"Simmonds","year":"1993","journal-title":"J. Gen. Virol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1099\/0022-1317-75-5-1053","article-title":"Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions","volume":"75","author":"Simmonds","year":"1994","journal-title":"J. Gen. Virol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1099\/0022-1317-76-10-2493","article-title":"Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: Implications for virus classification. The International HCV Collaborative Study Group","volume":"76","author":"Mellor","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-59745-394-3_4","article-title":"Nomenclature and numbering of the hepatitis C virus","volume":"510","author":"Kuiken","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2893.2008.01012.x","article-title":"Expert opinion on the treatment of patients with chronic hepatitis C","volume":"16","author":"Zeuzem","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.3748\/wjg.v20.i24.7555","article-title":"Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview","volume":"20","author":"Hotta","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-016-0685-x","article-title":"Genotype 3 Infection: The Last Stand of Hepatitis C Virus","volume":"77","author":"Chan","year":"2017","journal-title":"Drugs"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/B:DDAS.0000011597.92851.56","article-title":"Hepatic Steatosis in Hepatitis C Virus Genotype 3 Infection: Does It Correlate with Body Mass Index, Fibrosis, and HCV Risk Factors?","volume":"49","author":"Sharma","year":"2004","journal-title":"Dig. Dis. Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jhep.2009.01.019","article-title":"Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis","volume":"50","author":"Raimondi","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep.21826","article-title":"Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study","volume":"46","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/v7092857","article-title":"Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance","volume":"7","author":"Cuypers","year":"2015","journal-title":"Viruses"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3390\/v3102006","article-title":"Recombination in hepatitis C virus","volume":"3","author":"Bracho","year":"2011","journal-title":"Viruses"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Magiorkinis, G., Magiorkinis, E., Paraskevis, D., Ho, S.Y., Shapiro, B., Pybus, O.G., Allain, J.P., and Hatzakis, A. (2009). The global spread of hepatitis C virus 1a and 1b: A phylodynamic and phylogeographic analysis. PLoS Med., 6.","DOI":"10.4016\/15035.01"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.12669\/pjms.295.3610","article-title":"Hepatitis C genotype and associated risks factors of patients at University Kebangsaan Malaysia Medical Centre","volume":"29","author":"Mohamed","year":"2013","journal-title":"Pak. J. Med. Sci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcv.2016.05.010","article-title":"New findings in HCV genotype distribution in selected West European, Russian and Israeli regions","volume":"81","author":"Kartashev","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"15992","DOI":"10.3748\/wjg.v20.i43.15992","article-title":"Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy","volume":"20","author":"Preciado","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Li, H., Stoddard, M.B., Wang, S., Blair, L.M., Giorgi, E.E., Parrish, E.H., Learn, G.H., Hraber, P., Goepfert, P.A., and Saag, M.S. (2012). Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002880"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Mohamoud, Y.A., Mumtaz, G.R., Riome, S., Miller, D., and Abu-Raddad, L.J. (2013). The epidemiology of hepatitis C virus in Egypt: A systematic review and data synthesis. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-288"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1099\/vir.0.011569-0","article-title":"Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa","volume":"90","author":"Markov","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Irekeola, A.A., Malek, N.A., Wada, Y., Mustaffa, N., Muhamad, N.I., and Shueb, R.H. (2021). Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251673"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Yao, Y., Wu, W., Feng, R., Wu, Z., Cun, W., and Dong, S. (2013). Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082598"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1086\/587992","article-title":"Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan","volume":"46","author":"Liu","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1089-3261(02)00065-X","article-title":"Hepatitis C virus genetic variability: Pathogenic and clinical implications","volume":"7","author":"Pawlotsky","year":"2003","journal-title":"Clin. Liver Dis."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0168-8278(96)80194-2","article-title":"Biological and clinicopathological features associated with hepatitis C virus type 5 infections","volume":"24","author":"Murphy","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.meegid.2013.10.022","article-title":"Near full-length genome analysis of HCV genotype 5 strains from South Africa","volume":"21","author":"Gededzha","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1128\/JVI.80.9.4220-4226.2006","article-title":"Investigating the origin and spread of hepatitis C virus genotype 5a","volume":"80","author":"Verbeeck","year":"2006","journal-title":"J. Virol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1093\/gbe\/evv202","article-title":"Evolutionary and Phylogenetic Analysis of the Hepaciviruses and Pegiviruses","volume":"7","author":"Lowes","year":"2015","journal-title":"Genome Biol. Evol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.3201\/eid1812.120498","article-title":"Nonprimate hepaciviruses in domestic horses, United kingdom","volume":"18","author":"Lyons","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.meegid.2017.01.030","article-title":"First identification and phylogenetic analysis of equine hepacivirus in Korea","volume":"49","author":"Kim","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2014.12.014","article-title":"Surveying the global virome: Identification and characterization of HCV-related animal hepaciviruses","volume":"115","author":"Scheel","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Warnock, R.C., Parham, J.F., Joyce, W.G., Lyson, T.R., and Donoghue, P.C. (2015). Calibration uncertainty in molecular dating analyses: There is no substitute for the prior evaluation of time priors. Proc. Biol. Sci., 282.","DOI":"10.1098\/rspb.2014.1013"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/eri.09.8","article-title":"Acute hepatitis C: Prevention and treatment","volume":"7","author":"Ozaras","year":"2009","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_215","unstructured":"Kradin, R.L. (2018). Diagnostic Pathology of Infectious Disease, Elsevier. [2nd ed.]."},{"key":"ref_216","first-page":"1009","article-title":"Fulminant hepatic failure (FHF) due to acute hepatitis C","volume":"31","author":"Younis","year":"2015","journal-title":"Pak. J. Med. Sci."},{"key":"ref_217","first-page":"117","article-title":"Hepatitis C infection: A rare cause of fulminant hepatic failure","volume":"90","author":"Gordon","year":"1995","journal-title":"Am. J. Gastroenterol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1002\/hep.510260703","article-title":"Hepatitis C: The clinical spectrum of disease","volume":"26","author":"Hoofnagle","year":"1997","journal-title":"Hepatology"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2174\/138161208784746770","article-title":"Epidemiology of HCV Infection","volume":"14","author":"Baldo","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.3748\/wjg.v13.i41.5481","article-title":"Clinical significance of activity of ALT enzyme in patients with hepatitis C virus","volume":"13","author":"Akkaya","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1537-2995.2005.04390.x","article-title":"Dynamics of viremia in early hepatitis C virus infection","volume":"45","author":"Glynn","year":"2005","journal-title":"Transfusion"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/BF02071402","article-title":"Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection","volume":"41","author":"Ghany","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1189\/jlb.4RI0214-126R","article-title":"Immune control and failure in HCV infection--tipping the balance","volume":"96","author":"Dustin","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group","volume":"340","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1046\/j.1440-1746.2000.02276.x","article-title":"Hepatitis C virus clearance is prominent in women in an endemic area","volume":"15","author":"Inoue","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2893.1996.tb00104.x","article-title":"Higher elimination rate of hepatitis C virus among women","volume":"3","author":"Yamakawa","year":"1996","journal-title":"J. Viral Hepat."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2005-07-2781","article-title":"Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia","volume":"107","author":"Zhang","year":"2006","journal-title":"Blood"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1046\/j.1365-2516.2001.00559.x","article-title":"Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders","volume":"7","author":"Messick","year":"2001","journal-title":"Haemophilia"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1155\/2007\/796325","article-title":"Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users","volume":"21","author":"Grebely","year":"2007","journal-title":"Can. J. Gastroenterol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.1840400419","article-title":"Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population","volume":"40","author":"Piasecki","year":"2004","journal-title":"Hepatology"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"849373","DOI":"10.1155\/2012\/849373","article-title":"The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C","volume":"2012","author":"Bellanti","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Susser, S., Herrmann, E., Lange, C., Hamdi, N., M\u00fcller, T., Berg, T., Perner, D., Zeuzem, S., and Sarrazin, C. (2014). Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112592"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.gastro.2011.09.039","article-title":"Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection","volume":"142","author":"Beinhardt","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3892\/etm.2011.385","article-title":"Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis","volume":"3","author":"Wu","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: An update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Shen, C., Jiang, X., Li, M., and Luo, Y. (2023). Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers, 15.","DOI":"10.3390\/cancers15020533"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14218\/JCTH.2017.00067","article-title":"Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review","volume":"6","author":"Axley","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.4254\/wjh.v7.i14.1843","article-title":"Hepatitis C cirrhosis: New perspectives for diagnosis and treatment","volume":"7","author":"Khullar","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1665-2681(19)32176-3","article-title":"Dynamics of hepatitis C virus infection","volume":"1","author":"Zeuzem","year":"2002","journal-title":"Ann. Hepatol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2893.2010.01289.x","article-title":"Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia","volume":"18","author":"Gadalla","year":"2011","journal-title":"J. Viral Hepat."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/gut.2003.026393","article-title":"Fibrosis progression in chronic hepatitis C virus infection","volume":"53","author":"McCaughan","year":"2004","journal-title":"Gut"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"39409","DOI":"10.1038\/srep39409","article-title":"HBV\/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3748\/wjg.v22.i4.1357","article-title":"Liver pathology of hepatitis C, beyond grading and staging of the disease","volume":"22","author":"Dhingra","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/infdis\/jiw332","article-title":"Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection","volume":"214","author":"Zeremski","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"Sebastiani","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Khatun, M., and Ray, R.B. (2019). Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells, 8.","DOI":"10.3390\/cells8101249"},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Reungoat, E., Grigorov, B., Zoulim, F., and P\u00e9cheur, E.I. (2021). Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. Cancers, 13.","DOI":"10.3390\/cancers13092270"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/PAP.0000000000000312","article-title":"Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review","volume":"28","author":"Khan","year":"2021","journal-title":"Adv. Anat. Pathol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jhep.2014.07.010","article-title":"Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma","volume":"61","author":"Hoshida","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1042\/CS20060171","article-title":"Immunopathogenesis in hepatitis C virus cirrhosis","volume":"112","author":"Spengler","year":"2007","journal-title":"Clin. Sci."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.clinthera.2015.05.507","article-title":"Understanding the Complexities of Cirrhosis","volume":"37","author":"Muir","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0041-1725023","article-title":"The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone","volume":"41","author":"Haep","year":"2021","journal-title":"Semin. Liver Dis."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3748\/wjg.v27.i33.5536","article-title":"Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?","volume":"27","author":"Demirtas","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3748\/wjg.v28.i14.1405","article-title":"Viral hepatitis: Past, present, and future","volume":"28","author":"Odenwald","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Virz\u00ec, A., Roca Suarez, A.A., Baumert, T.F., and Lupberger, J. (2018). Oncogenic Signaling Induced by HCV Infection. Viruses, 10.","DOI":"10.3390\/v10100538"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.cmi.2016.07.019","article-title":"Molecular mechanisms of hepatitis C virus\u2013induced hepatocellular carcinoma","volume":"22","author":"Vescovo","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Goto, K., Roca Suarez, A.A., Wrensch, F., Baumert, T.F., and Lupberger, J. (2020). Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093057"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3748\/wjg.v25.i1.42","article-title":"Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma","volume":"25","author":"Mahmoudvand","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Pascut, D., Hoang, M., Nguyen, N.N.Q., Pratama, M.Y., and Tiribelli, C. (2021). HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers, 13.","DOI":"10.3390\/cancers13102485"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4254\/wjh.v9.i36.1305","article-title":"Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection","volume":"9","author":"Irshad","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/hep.14.7","article-title":"Mechanisms of hepatocarcinogenesis in chronic hepatitis C","volume":"1","author":"Mitchell","year":"2014","journal-title":"Hepat. Oncol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"172","DOI":"10.14218\/JCTH.2018.00049","article-title":"HCV Extrahepatic Manifestations","volume":"7","author":"Kuna","year":"2019","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13027-016-0076-7","article-title":"Systemic manifestations of hepatitis C infection","volume":"11","author":"Tang","year":"2016","journal-title":"Infect. Agent. Cancer"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3350\/cmh.2022.0349","article-title":"Acute hepatitis C virus infection: Clinical update and remaining challenges","volume":"29","author":"Liu","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC Recommendations for Hepatitis C Screening Among Adults\u2014United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel (2011). Acute hepatitis C in HIV-infected individuals: Recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS, 25, 399\u2013409.","DOI":"10.1097\/QAD.0b013e328343443b"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.clinthera.2020.06.012","article-title":"Screening for Hepatitis C Virus: How Universal Is Universal?","volume":"42","author":"Jhaveri","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3350\/cmh.2021.0193","article-title":"Cost-effectiveness of chronic hepatitis C screening and treatment","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"240","DOI":"10.37201\/req\/030.2020","article-title":"Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence","volume":"33","author":"Ledesma","year":"2020","journal-title":"Rev. Esp. Quim."},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Shahid, I., Alzahrani, A.R., Al-Ghamdi, S.S., Alanazi, I.M., Rehman, S., and Hassan, S. (2021). Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics, 11.","DOI":"10.3390\/diagnostics11071253"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/cid\/cix798","article-title":"Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings","volume":"66","author":"Assoumou","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/acem.13932","article-title":"Centers for Disease Control and Prevention Recommendations for Hepatitis C Testing: The Need to Adopt Universal Screening in an Appalachian Emergency Department","volume":"27","author":"Wojcik","year":"2020","journal-title":"Acad. Emerg. Med."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"e003194","DOI":"10.1136\/bmjgh-2020-003194","article-title":"Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: A societal perspective","volume":"5","author":"Wei","year":"2020","journal-title":"BMJ Glob. Health"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: A global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Warkad, S.D., Song, K.S., Pal, D., and Nimse, S.B. (2019). Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies. Sensors, 19.","DOI":"10.3390\/s19194257"},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Tang, W., Chen, W., Amini, A., Boeras, D., Falconer, J., Kelly, H., Peeling, R., Varsaneux, O., Tucker, J.D., and Easterbrook, P. (2017). Diagnostic accuracy of tests to detect Hepatitis C antibody: A meta-analysis and review of the literature. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2773-2"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/cid\/cis368","article-title":"Laboratory diagnostics for hepatitis C virus infection","volume":"55","author":"Kamili","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0973-6247.126683","article-title":"Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays","volume":"8","author":"Gupta","year":"2014","journal-title":"Asian J. Transfus. Sci."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/JCM.40.12.4407-4412.2002","article-title":"Laboratory assays for diagnosis and management of hepatitis C virus infection","volume":"40","author":"Richter","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"15476","DOI":"10.3748\/wjg.v20.i42.15476","article-title":"Diagnostic tests for hepatitis C: Recent trends in electrochemical immunosensor and genosensor analysis","volume":"20","author":"Uliana","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/nn102873w","article-title":"Rapid screening of genetic biomarkers of infectious agents using quantum dot barcodes","volume":"5","author":"Giri","year":"2011","journal-title":"ACS Nano"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7754\/Clin.Lab.2016.161113","article-title":"Hepatitis C: An Overview of Various Laboratory Assays with their Mode of Diagnostic Cooperation","volume":"63","author":"Safi","year":"2017","journal-title":"Clin. Lab."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7754\/Clin.Lab.2013.130634","article-title":"HCV antigen testing for the diagnosis of hepatitis C infection: A cost-efficient algorithm","volume":"60","author":"Kadkhoda","year":"2014","journal-title":"Clin. Lab."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"742722","DOI":"10.3389\/fviro.2021.742722","article-title":"Rapid Diagnostics for Hepatitis B and C Viruses in Low- and Middle-Income Countries","volume":"1","author":"Shenge","year":"2021","journal-title":"Front. Virol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1743-422X-7-117","article-title":"A novel duplex real-time reverse transcriptase-polymerase chain reaction assay for the detection of hepatitis C viral RNA with armored RNA as internal control","volume":"7","author":"Meng","year":"2010","journal-title":"Virol. J."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1574-695X.2011.00828.x","article-title":"Rapid detection of hepatitis C virus RNA by a reverse transcription loop-mediated isothermal amplification assay","volume":"63","author":"Wang","year":"2011","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jmv.23216","article-title":"Transcription-mediated amplification (TMA) for the assessment of viremia in hemodialysis patients with hepatitis C","volume":"84","author":"Bastos","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1309\/90BU6KDXANFLN4RJ","article-title":"Branched DNA technology in molecular diagnostics","volume":"126","author":"Tsongalis","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol., 69, 461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"e22045","DOI":"10.1002\/jcla.22045","article-title":"Comparison of Three Different Hepatitis C Virus Genotyping Methods: 5\u2019NCR PCR-RFLP, Core Type-Specific PCR, and NS5b Sequencing in a Tertiary Care Hospital in South India","volume":"31","author":"Daniel","year":"2017","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1155\/2009\/370651","article-title":"Liver biopsies for chronic hepatitis C: Should nonultrasound-guided biopsies be abandoned?","volume":"23","author":"Flemming","year":"2009","journal-title":"Can. J. Gastroenterol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cgh.2010.03.025","article-title":"Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial","volume":"8","author":"Seeff","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/13814788.2022.2056161","article-title":"Chronic hepatitis C: Diagnosis and treatment made easy","volume":"28","author":"Elhoashla","year":"2022","journal-title":"Eur. J. Gen. Pr."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.24013","article-title":"Noninvasive assessment of liver fibrosis","volume":"53","author":"Crespo","year":"2011","journal-title":"Hepatology"},{"key":"ref_301","doi-asserted-by":"crossref","unstructured":"Florea, M., Serban, T., Tirpe, G.R., Tirpe, A., and Lupsor-Platon, M. (2021). Noninvasive Assessment of Hepatitis C Virus Infected Patients Using Vibration-Controlled Transient Elastography. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122575"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hepr.13333","article-title":"Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C","volume":"49","author":"Fujita","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3748\/wjg.v20.i11.2854","article-title":"Non-invasive diagnosis of liver fibrosis in chronic hepatitis C","volume":"20","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_304","first-page":"140953","article-title":"Evolution of interferon-based therapy for chronic hepatitis C","volume":"2010","author":"Chen","year":"2010","journal-title":"Hepat. Res. Treat."},{"key":"ref_305","doi-asserted-by":"crossref","unstructured":"Hansen, N., Obel, N., Christensen, P.B., Kj\u00e6r, M., Laursen, A.L., Krarup, H.B., M\u00f8ller, A., Schlichting, P., Bukh, J., and Weis, N. (2011). Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study. BMC Infect. Dis., 11.","DOI":"10.1186\/1471-2334-11-177"},{"key":"ref_306","doi-asserted-by":"crossref","unstructured":"Lynch, E.N., and Russo, F.P. (2023). Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062195"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/jac\/dks485","article-title":"Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients","volume":"68","author":"Donato","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Awasthi, A., Katiyar, H., Rungta, S., Deep, A., Kumar, V., Kumar, A., Tiwari, P., and Goel, A. (2023). Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-na\u00efve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial). PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285725"},{"key":"ref_309","first-page":"1460","article-title":"Efficacy of 8- versus 12-week treatment with ledipasvir\/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting","volume":"18","author":"Piekarska","year":"2022","journal-title":"Arch. Med. Sci."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s40121-023-00823-z","article-title":"Real-World Effectiveness of 8-Week Glecaprevir\/Pibrentasvir in Treatment-Na\u00efve, Compensated Cirrhotic HCV Patients","volume":"12","author":"Reau","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s43066-022-00226-8","article-title":"The art of managing hepatitis C virus in special population groups: A paradigm shift","volume":"12","author":"Elbadry","year":"2022","journal-title":"Egypt. Liver J."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijantimicag.2018.12.010","article-title":"Hepatitis C virus therapy: No one will be left behind","volume":"53","author":"Pietri","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1665-2681(19)32118-0","article-title":"Side effects of medical therapy for chronic hepatitis C","volume":"3","author":"Shiffman","year":"2004","journal-title":"Ann. Hepatol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: Efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1086\/376971","article-title":"Hematologic disorders associated with hepatitis C virus infection and their management","volume":"37","author":"Dieterich","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.3748\/wjg.v27.i23.3249","article-title":"Update on the management and treatment of viral hepatitis","volume":"27","author":"Almeida","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.3748\/wjg.v18.i43.6183","article-title":"Telaprevir\/boceprevir era: From bench to bed and back","volume":"18","author":"Pan","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QCO.0000000000000190","article-title":"A new era of therapy for hepatitis C virus infection","volume":"28","author":"Nyalakonda","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1155\/2012\/751057","article-title":"Review of boceprevir and telaprevir for the treatment of chronic hepatitis C","volume":"26","author":"Wilby","year":"2012","journal-title":"Can. J. Gastroenterol."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","article-title":"Sofosbuvir, a Significant Paradigm Change in HCV Treatment","volume":"3","author":"McQuaid","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_321","first-page":"256","article-title":"Ledipasvir\/Sofosbuvir (harvoni): Improving options for hepatitis C virus infection","volume":"40","author":"Gritsenko","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40265-017-0739-8","article-title":"Elbasvir\/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3748\/wjg.v29.i6.949","article-title":"Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C","volume":"29","author":"Invernizzi","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): A multicentre, open-label, non-randomised, phase 3 study","volume":"385","author":"Molina","year":"2015","journal-title":"Lancet"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_328","doi-asserted-by":"crossref","unstructured":"Smith-Palmer, J., Cerri, K., and Valentine, W. (2015). Achieving sustained virologic response in hepatitis C: A systematic review of the clinical, economic and quality of life benefits. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0748-8"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2020-4-11","article-title":"Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: A large, field-practice study","volume":"9","author":"Sacco","year":"2020","journal-title":"Drugs Context"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3350\/cmh.2020.0230","article-title":"Current and future strategies for the treatment of chronic hepatitis C","volume":"27","author":"Alshuwaykh","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jfma.2022.01.012","article-title":"Ledipasvir\/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan","volume":"121","author":"Lo","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/gutjnl-2017-315906","article-title":"Ledipasvir\/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: Results from a randomised phase III study in Egypt","volume":"68","author":"Shiha","year":"2019","journal-title":"Gut"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(15)00529-0","article-title":"Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: An open-label, multicentre, single-arm, phase 2 study","volume":"16","author":"Abergel","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2017.399","article-title":"Open Label Study of 8 vs. 12 Weeks of Ledipasvir\/Sofosbuvir in Genotype 6 Treatment Na\u00efve or Experienced Patients","volume":"112","author":"Nguyen","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.3390\/cimb45100521","article-title":"A Synopsis of Hepatitis C Virus Treatments and Future Perspectives","volume":"45","author":"Medina","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5114\/ceh.2020.95566","article-title":"Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir\/daclatasvir combination. A randomized, placebo-controlled, double-blinded study","volume":"6","author":"Mohamed","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1093\/infdis\/jiad199","article-title":"Opportunities for Enhanced Prevention and Control of Hepatitis C Through Improved Screening and Testing Efforts","volume":"229","author":"Cartwright","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41124-018-0033-8","article-title":"Hepatitis C virus prevention and care for drug injectors: The French approach","volume":"3","author":"Delile","year":"2018","journal-title":"Hepatol. Med. Policy"},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3138\/canlivj.1.2.003","article-title":"The role of prevention strategies in achieving HCV elimination in Canada: What are the remaining challenges?","volume":"1","author":"Minoyan","year":"2018","journal-title":"Can. Liver J."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/cis392","article-title":"Hepatitis C virus prevention, care, and treatment: From policy to practice","volume":"55","author":"Ward","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"101810","DOI":"10.1016\/j.eclinm.2022.101810","article-title":"Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019","volume":"56","author":"Stewart","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_351","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group (2018). KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. Suppl., 8, 91\u2013165.","DOI":"10.1016\/j.kisu.2018.06.001"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0040-1713657","article-title":"Simplification of Care for Chronic Hepatitis C Virus Infection","volume":"40","author":"Pawlotsky","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3350\/cmh.2021.0236","article-title":"A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/hepr.13478","article-title":"Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan","volume":"50","author":"Nagai","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane Review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/add.13089","article-title":"Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: Results from the ANRS-AERLI intervention study","volume":"111","author":"Roux","year":"2016","journal-title":"Addiction"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4254\/wjh.v10.i9.549","article-title":"Challenge of hepatitis C in Egypt and hepatitis B in Mauritania","volume":"10","author":"Raad","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_358","doi-asserted-by":"crossref","unstructured":"Pan, C.Q., and Park, J.S. (2024). Revamping hepatitis C global eradication efforts: Towards simplified and enhanced screening, prevention, and treatment. Transl. Gastroenterol. Hepatol., 9.","DOI":"10.21037\/tgh-23-104"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4254\/wjh.v11.i5.421","article-title":"Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China","volume":"11","author":"Xie","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"1187786","DOI":"10.3389\/fpubh.2023.1187786","article-title":"Treatment as prevention for hepatitis C virus in the Middle East and North Africa: A modeling study","volume":"11","author":"Ayoub","year":"2023","journal-title":"Front. Public Health"},{"key":"ref_361","doi-asserted-by":"crossref","unstructured":"Colpitts, C.C., and Baumert, T.F. (2016). Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure. Viruses, 8.","DOI":"10.3390\/v8080226"},{"key":"ref_362","doi-asserted-by":"crossref","unstructured":"Malandris, K., Kalopitas, G., Theocharidou, E., and Germanidis, G. (2021). The Role of RASs \/RVs in the Current Management of HCV. Viruses, 13.","DOI":"10.3390\/v13102096"},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"e32579","DOI":"10.7554\/eLife.32579","article-title":"Transmission genetics of drug-resistant hepatitis C virus","volume":"7","author":"Tellinghuisen","year":"2018","journal-title":"eLife"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jmv.21658","article-title":"Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form_2b6w","volume":"82","author":"Lee","year":"2010","journal-title":"J. Med. Virol."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.mcna.2023.01.001","article-title":"Chronic Hepatitis C: Advances in Therapy and the Remaining Challenges","volume":"107","author":"Alqahtani","year":"2023","journal-title":"Med. Clin. N. Am."},{"key":"ref_366","doi-asserted-by":"crossref","unstructured":"Ribeiro, R.M., Li, H., Wang, S., Stoddard, M.B., Learn, G.H., Korber, B.T., Bhattacharya, T., Guedj, J., Parrish, E.H., and Hahn, B.H. (2012). Quantifying the diversification of hepatitis C virus (HCV) during primary infection: Estimates of the in vivo mutation rate. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002881"},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0031-1297925","article-title":"New insights into the HCV quasispecies and compartmentalization","volume":"31","author":"Farci","year":"2011","journal-title":"Semin. Liver Dis."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.02386-13","article-title":"Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors","volume":"58","author":"Cento","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0b013e328363b1f9","article-title":"Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C","volume":"27","author":"Leggewie","year":"2013","journal-title":"AIDS"},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4103\/jfmpc.jfmpc_943_19","article-title":"Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature","volume":"9","author":"Bhatia","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"105562","DOI":"10.1016\/j.ijantimicag.2018.10.005","article-title":"Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance","volume":"56","author":"Perales","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"a036947","DOI":"10.1101\/cshperspect.a036947","article-title":"Challenges and Promise of a Hepatitis C Virus Vaccine","volume":"10","author":"Cox","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_377","first-page":"265","article-title":"Drug Pricing & Challenges to Hepatitis C Treatment Access","volume":"14","author":"Henry","year":"2018","journal-title":"J. Health Biomed. Law."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2015.01.004","article-title":"A path to eradication of hepatitis C in low- and middle-income countries","volume":"119","author":"Graham","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_379","doi-asserted-by":"crossref","unstructured":"Khalsa, J.H., and Mathur, P. (2021). Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. Viruses, 13.","DOI":"10.3390\/v13071363"},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, Progress, and Challenges to Hepatitis C Vaccine Development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1084\/jem.20050808","article-title":"Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man","volume":"201","author":"Bowen","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1128\/JVI.03717-14","article-title":"Transmitted\/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection","volume":"89","author":"Bull","year":"2015","journal-title":"J. Virol."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat. Med."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1002\/iid3.977","article-title":"Therapeutic strategies and promising vaccine for hepatitis C virus infection","volume":"11","author":"Adugna","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_385","doi-asserted-by":"crossref","unstructured":"Schlotthauer, F., McGregor, J., and Drummer, H.E. (2021). To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses, 13.","DOI":"10.3390\/v13050805"},{"key":"ref_386","doi-asserted-by":"crossref","unstructured":"Duncan, J.D., Urbanowicz, R.A., Tarr, A.W., and Ball, J.K. (2020). Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines, 8.","DOI":"10.3390\/vaccines8010090"},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"14085","DOI":"10.1038\/s41598-019-50365-z","article-title":"HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen","volume":"9","author":"Filskov","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"e00055-19","DOI":"10.1128\/JVI.00055-19","article-title":"Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV","volume":"93","author":"Ljungberg","year":"2019","journal-title":"J. Virol."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/epidemiologia5020011","article-title":"The COVID-19 Pandemic Affected Hepatitis C Virus Circulation and Genotypic Frequencies-Implications for Hepatitis C Prevention, Treatment and Research","volume":"5","author":"Chies","year":"2024","journal-title":"Epidemiologia"},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41541-023-00635-9","article-title":"Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity","volume":"8","author":"Patra","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/liv.14222","article-title":"Innovative strategies for the elimination of viral hepatitis at a national level: A country case series","volume":"39","author":"Pedrana","year":"2019","journal-title":"Liver Int."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.3748\/wjg.v24.i44.4959","article-title":"Hepatitis elimination by 2030: Progress and challenges","volume":"24","author":"Waheed","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_394","unstructured":"The Coalition for Global Hepatitis Elimination (2024, April 28). About the Coalition. Available online: https:\/\/www.globalhep.org\/about\/about-coalition."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3748\/wjg.v22.i25.5837","article-title":"Towards safe injection practices for prevention of hepatitis C transmission in South Asia: Challenges and progress","volume":"22","author":"Janjua","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_396","doi-asserted-by":"crossref","unstructured":"Othman, B., Barakat, M., Omar, A., Al-Rawashdeh, A., Qashou, Y., Zrieq, R., and Al-Najjar, M.A.A. (2022). Evaluation of hepatitis B knowledge, practices, and beliefs among the Jordanian population: A cross-sectional study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0277186"},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12954-023-00743-8","article-title":"Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: Results from a global values and preferences survey","volume":"20","author":"Villes","year":"2023","journal-title":"Harm Reduct. J."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/6\/1035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:45:43Z","timestamp":1760107543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/6\/1035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":397,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["microorganisms12061035"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms12061035","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}